Disis, M. L., Liao, J. B., Higgins, D. M., Childs, J. S., Stanton, S. E., Tinker, A. V., . . . Goff, B. A. (2021). Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: Survival and immune correlates. BMJ Publishing Group.
Style de citation Chicago (17e éd.)Disis, Mary L., et al. Pembrolizumab with Low-dose Carboplatin for Recurrent Platinum-resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: Survival and Immune Correlates. BMJ Publishing Group, 2021.
Style de citation MLA (8e éd.)Disis, Mary L., et al. Pembrolizumab with Low-dose Carboplatin for Recurrent Platinum-resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: Survival and Immune Correlates. BMJ Publishing Group, 2021.